2024
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S, Denkert C, Park Y, Hui R, Harbeck N, Takahashi M, Im S, Untch M, Fasching P, Mouret-Reynier M, Foukakis T, Ferreira M, Cardoso F, Zhou X, Karantza V, Tryfonidis K, Aktan G, O'Shaughnessy J. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. New England Journal Of Medicine 2024 PMID: 39282906, DOI: 10.1056/nejmoa2409932.Peer-Reviewed Original ResearchEarly-stage triple-negative breast cancerTriple-negative breast cancerPembrolizumab-chemotherapy groupPlacebo-chemotherapy groupCycles of pembrolizumabPathological complete responseEvent-free survivalOverall survivalBreast cancerAdjuvant pembrolizumabComplete responseSafety profile of pembrolizumabData cutoff dateUntreated stage IIPlatinum-containing chemotherapyMedian follow-upEstimate overall survivalSecondary end pointsEpirubicin-cyclophosphamideNeoadjuvant pembrolizumabNeoadjuvant therapyDoxorubicin-cyclophosphamideNeoadjuvant chemotherapyDefinitive surgeryPembrolizumab
2020
EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors.
Bruce J, Pusztai L, Braiteh F, Gorla S, Wu C, Baranda J. EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors. Journal Of Clinical Oncology 2020, 38: tps3647-tps3647. DOI: 10.1200/jco.2020.38.15_suppl.tps3647.Peer-Reviewed Original ResearchNon-small cell lung cancerSafety/tolerabilityUrothelial carcinomaNectin-4Gastroesophageal cancerBreast cancerOpen-label phase 2 studySolid tumorsDose reduction/interruptionMonoclonal antibody-drug conjugatesActive CNS metastasesHigh-dose steroidsReduction/interruptionTumor-specific cohortsUncontrolled diabetes mellitusDisease control rateMetastatic urothelial carcinomaObjective response ratePhase II studyPlatinum-containing chemotherapyPhase 2 studyMetastatic solid tumorsPD-L1 inhibitorsTreatment of adultsCell lung cancer